FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $561,176 | -66.4% | 98,452 | -40.5% | 0.05% | -73.8% |
| Q4 2022 | $1,670,026 | +93.7% | 165,513 | +330.5% | 0.20% | +191.0% |
| Q3 2022 | $862,000 | -62.6% | 38,451 | -58.6% | 0.07% | -64.6% |
| Q2 2022 | $2,304,000 | +821.6% | 92,987 | +2964.8% | 0.19% | +243.6% |
| Q1 2021 | $250,000 | -52.3% | 3,034 | -47.4% | 0.06% | -66.7% |
| Q4 2020 | $524,000 | – | 5,765 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |